Authors



Kristen K. Ciombor, MD, MSCI

Latest:

Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC

The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.


Anna Howard, RN

Latest:

Managing Hematological Toxicities Associated with Bispecifics in MM

Experts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.




Jared Kaltwasser

Latest:

Addition of Sintilimab to Bevacizumab Biosimilar IBI305 and Chemo Boosts PFS vs Chemo in Advanced EGFR-Mutant NSCLC

Patients with locally advanced or metastatic EGFR-mutant nonsquamous non–small cell lung cancer who progressed on an EGFR inhibitor may benefit from treatment with sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy vs chemotherapy alone.



Ludovic Saba, MD

Latest:

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.


Anna Hecksher, BS

Latest:

Integrative Oncology in Young Women With Breast Cancer

Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.



Claudia Calderon, NP

Latest:

Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer

Experts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.


Ash Tewari, MD, MBBS, MCh, FRCS

Latest:

Protecting Sexual Function Via The Hood Technique in Prostate Cancer

“Even after doing 10,000 of these operations, we are tweaking [the hood technique]…to make things better,” according to Ash Tewari, MD, MBBS, MCh, FRCS.


Denise Myshko

Latest:

Preferred Treatment of RAS Wild-Type, BRAF V600E Mutant mCRC Favors Bevacizumab Over Cetuximab

Certain patients with RAS wild-type colorectal cancer should be treated with bevacizumab in place of cetuximab in combination with FOLFOXIRI.



Joselle Cook, M.B.B.S

Latest:

Exploring Novel Treatment Options in Patients With RRMM

The panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.




Natasha Lewis, MD

Latest:

Current Treatment of Peripheral T-cell Lymphoma

This review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.


Suzanne P. MacFarland, MD

Latest:

Liquid Biopsy Imaging May Show Benefit in Li-Fraumeni Syndrome Screening

Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.


Valentina Lombardo

Latest:

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy

A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.


Nerina T. McDonald, PA-C

Latest:

Advanced Bladder Cancer: Future Directions in Care

Closing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.


Samantha A. Armstrong, MD

Latest:

Molecular Profiling in Metastatic Colorectal Cancer

ABSTRACT: Colorectal cancer (CRC) is a commonly diagnosed malignancy. Although chemotherapy remains the backbone of treatment, the landscape of treating metastatic CRC (mCRC) is changing with the understanding of its heterogeneity and molecular blueprint. Colon cancer sidedness has proven to hold prognostic implications, with right-sided tumors having higher incidence of BRAF and KRAS mutations and being microsatellite instability–high (MSI-H); overall, they have a worse prognosis compared with left sided-tumors. Results of molecular research have demonstrated the need to profile each mCRC patient for RAS and BRAF mutations, MSI-H status, HER2 amplifications, and NTRK fusions. Ongoing clinical trials using targeted agents aim to further improve survival outcomes. We emphasize the epidemiology, knowledge of primary tumor location, and mutational landscape of mCRC, as well as novel treatment options for patients harboring unique subtypes of these characteristics.


Linda E. Carlson, PhD

Latest:

Updated SIO/ASCO Guidelines Recommend Integrative Therapies to Reduce Anxiety/Depression in Patients With Cancer

Linda E. Carlson, PhD, RPsych, discusses the recent updates from SIO/ASCO to the anxiety and depression guidelines for patients with cancer.


Christian Stief, MD

Latest:

Value of Geriatric Assessment in Patients With Genitourinary Carcinoma

This work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.



Jeremy S. Abramson MD, MMSc

Latest:

Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas

P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.


Shyam Sundar S, BDS, MDS

Latest:

Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case Report

A case study by Sahith Kumar Shetty, BDS, MDS, et al reviews the need for a multidisciplinary approach to the treatment of patients with Gorlin-Goltz syndrome.




Manju George, PhD

Latest:

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.